Most Recent

image: More Retractions for Fallen Scientist

More Retractions for Fallen Scientist

By | February 7, 2014

Molecular and Cellular Biology pulls five papers from endocrinologist Shigeaki Kato.

1 Comment

image: Opinion: Confronting Creationism

Opinion: Confronting Creationism

By | February 7, 2014

Molecular and Cellular Biology pulls five papers from endocrinologist Shigeaki Kato.

53 Comments

image: Week in Review: February 3–7

Week in Review: February 3–7

By | February 7, 2014

Molecular and Cellular Biology pulls five papers from endocrinologist Shigeaki Kato.

0 Comments

image: Stem Cell Lines Not Fit for Clinic

Stem Cell Lines Not Fit for Clinic

By | February 6, 2014

Molecular and Cellular Biology pulls five papers from endocrinologist Shigeaki Kato.

0 Comments

image: Judges Side with FDA on Stem Cells

Judges Side with FDA on Stem Cells

By | February 6, 2014

Molecular and Cellular Biology pulls five papers from endocrinologist Shigeaki Kato.

0 Comments

image: An Offensive Playbook

An Offensive Playbook

By | February 1, 2014

Molecular and Cellular Biology pulls five papers from endocrinologist Shigeaki Kato.

0 Comments

image: Book Excerpt from <em>Buddhist Biology</em>

Book Excerpt from Buddhist Biology

By | February 1, 2014

Molecular and Cellular Biology pulls five papers from endocrinologist Shigeaki Kato.

10 Comments

image: Meiosis Maven

Meiosis Maven

By | February 1, 2014

Molecular and Cellular Biology pulls five papers from endocrinologist Shigeaki Kato.

1 Comment

image: Self-Improvement Through the Ages

Self-Improvement Through the Ages

By | February 1, 2014

Molecular and Cellular Biology pulls five papers from endocrinologist Shigeaki Kato.

2 Comments

image: Week in Review: January 27–31

Week in Review: January 27–31

By | January 31, 2014

Molecular and Cellular Biology pulls five papers from endocrinologist Shigeaki Kato.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech